[HTML][HTML] Delivering safer immunotherapies for cancer
Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new
drug approvals and a massive pipeline of additional treatments in clinical and preclinical …
drug approvals and a massive pipeline of additional treatments in clinical and preclinical …
Infectious complications of biological and small molecule targeted immunomodulatory therapies
The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …
immunosuppression. We have moved from relying on broadly active traditional medications …
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
C Casulo, J Maragulia, AD Zelenetz - Clinical Lymphoma Myeloma and …, 2013 - Elsevier
Background Rituximab has altered the treatment approach to B-cell malignancies and other
diseases. Reports consider that rituximab had limited impact on serum immunoglobulins …
diseases. Reports consider that rituximab had limited impact on serum immunoglobulins …
Impact of rituximab on COVID-19 outcomes
H Levavi, G Lancman, J Gabrilove - Annals of hematology, 2021 - Springer
Rituximab is associated with prolonged B-cell depletion and secondary
hypogammaglobulinemia and is associated with a dampened humoral response and …
hypogammaglobulinemia and is associated with a dampened humoral response and …
Epidemiology of infections in cancer patients
TR Zembower - Infectious complications in cancer patients, 2014 - Springer
Although major advances in the care of cancer patients over the past several decades have
resulted in improved survival, infectious complications remain a significant cause of …
resulted in improved survival, infectious complications remain a significant cause of …
Rituximab-associated infections
JC Gea-Banacloche - Seminars in hematology, 2010 - Elsevier
After more than 10 years of use, rituximab has proven to be remarkably safe. However,
accumulated evidence now suggests that under some circumstances it may significantly …
accumulated evidence now suggests that under some circumstances it may significantly …
Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients
M Khellaf, A Charles-Nelson, O Fain… - Blood, The Journal …, 2014 - ashpublications.org
We conducted a prospective multicenter registry of 248 adult patients with immune
thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response …
thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response …
[HTML][HTML] Does rituximab increase the incidence of infectious complications? A narrative review
Background: Rituximab has increasingly been used for the treatment of hematological
malignancies and autoimmune diseases, and its efficacy and safety are well established …
malignancies and autoimmune diseases, and its efficacy and safety are well established …
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
EAA Christou, G Giardino, A Worth… - … Reviews of Immunology, 2017 - Taylor & Francis
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of
hematological malignancies and autoimmune diseases. The use of RTX is related to the …
hematological malignancies and autoimmune diseases. The use of RTX is related to the …
Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes
M Makatsori, S Kiani-Alikhan, AL Manson… - … Journal of Medicine, 2014 - academic.oup.com
Background: Rituximab, a chimeric monoclonal antibody against CD20, is increasingly used
in the treatment of B-cell lymphomas and autoimmune conditions. Transient peripheral B …
in the treatment of B-cell lymphomas and autoimmune conditions. Transient peripheral B …